Clarity Pharmaceuticals Ltd (CLRPF) Price

Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. The company is headquartered in Eveleigh, New South Wales. The company went IPO on 2021-08-25. The firm is focused on developing targeted copper theranostics based on its SAR Technology Platform. The company is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.